Trinity Delta view: The first-in-human trial of Scancell’s Modi-1 vaccine is a key step that could provide important information on the safety and immunogenicity of this novel approach, with the latter providing valuable early indications of potential efficacy. Assuming a smooth roll-out to the other study centres and no recruitment issues, early safety and immunogenicity data should be available by H222, and early efficacy results during 2023. Scancell has four novel inter-related technology platforms: ImmunoBody, Moditope, Glymabs, and AvidiMab. The ImmunoBody and Moditope oncology vaccines offer different approaches to treat intractable cancers both as monotherapy and in combination with agents such as CPIs. We value Scancell using an rNPV model and the Moditope programme is the largest contributor to our 29.1p/share (24.2p fully diluted) valuation, accounting for 11.9p (9.9p fully diluted). Successful clinical outcomes with Modi-1 would validate the Moditope platform and would lead, in our view, to material upside.
13 Jun 2022
Trinity Delta Lighthouse: Scancell
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Trinity Delta Lighthouse: Scancell
Scancell Holdings Plc (SCLP:LON) | 9.6 0 0.5% | Mkt Cap: 89.1m
- Published:
13 Jun 2022 -
Author:
Franc Gregori | Lala Gregorek | Philippa Gardner -
Pages:
2
Trinity Delta view: The first-in-human trial of Scancell’s Modi-1 vaccine is a key step that could provide important information on the safety and immunogenicity of this novel approach, with the latter providing valuable early indications of potential efficacy. Assuming a smooth roll-out to the other study centres and no recruitment issues, early safety and immunogenicity data should be available by H222, and early efficacy results during 2023. Scancell has four novel inter-related technology platforms: ImmunoBody, Moditope, Glymabs, and AvidiMab. The ImmunoBody and Moditope oncology vaccines offer different approaches to treat intractable cancers both as monotherapy and in combination with agents such as CPIs. We value Scancell using an rNPV model and the Moditope programme is the largest contributor to our 29.1p/share (24.2p fully diluted) valuation, accounting for 11.9p (9.9p fully diluted). Successful clinical outcomes with Modi-1 would validate the Moditope platform and would lead, in our view, to material upside.